Exploring the Differential Effectiveness of ICS by Smoking Status in COPD
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.
Our findings explores the emerging evidence that inhaled corticosteroids (ICS) may be less effective in current smokers compared with nonsmokers with chronic obstructive pulmonary disorder (COPD), says Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester.
The findings were presented at the
Transcript
What specific advantages does long-acting β-agonist plus long-acting muscarinic agonist (LABA+LAMA) therapy offer over LABA plus ICS in managing COPD symptoms in current smokers?
There have been studies suggesting that the inhaled corticosteroids are not as effective in current smokers compared to ex-smokers. In our analysis of the
Then when we looked at groups of patients that we know from our analysis are respondents—people who have a significant suppression of their blood eosinophils on inhaled steroids—in this group of patients, in ex-smokers, LABA+ICS was superior to LABA+LAMA; that's as we would have expected. Now, when we looked at the subgroup of current smokers, LABA+LAMA was consistently superior to LABA+ICS, and that tell us that probably current smokers don't get the same benefit from inhaled corticosteroids.
How might the findings from the FLAME trial post hoc analysis influence treatment guidelines for patients with COPD who are current smokers, particularly those with varying eosinophil counts?
Our post hoc analysis of the FLAME trial is an exploratory study, so we still need to validate our findings. We have a good message, but we need to further validate the results before having strong enough evidence to inform guidelines. So, what we have been doing is that we have started an individual participant data meta-analysis called the
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
September 17th 2025
- Cost-Effectiveness of Varying Weight Loss Interventions: Elena Losina, PhD
September 17th 2025
- Transforming Addiction Care: From Stigma to Support
September 16th 2025